Quince Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 11.15 million compared to USD 12.25 million a year ago. Basic loss per share from continuing operations was USD 0.26 compared to USD 0.34 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.79 USD | -5.99% | -4.82% | -24.76% |
Jun. 05 | Transcript : Quince Therapeutics, Inc. - Shareholder/Analyst Call | |
Jun. 03 | Quince Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EryDex System | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-24.76% | 34.14M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- QNCX Stock
- News Quince Therapeutics, Inc.
- Quince Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024